Circulation Journal Official Journal of the Japanese Circulation Society http://www. j-circ.or.jp s a treatment for acute myocardial infarction (AMI), thrombolytic therapy was started in the early 1980 s, 1 and now the best strategy is reperfusion of the occluded coronary artery and restoration of coronary blood flow with percutaneous coronary intervention (PCI) early after the onset of AMI. 2 Despite the fact that the outcome of AMI has improved with the reperfusion strategy, morbidity and mortality after AMI still remain significant.
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ejection fraction (LVEF), infarct size, or clinical events, but did increase the incidence of pulmonary edema. 9, 10 In the primary PCI era, pretreatment with intravenous β-blocker infusion before primary PCI reduced in-hospital death and improved mortality. 11, 12 Overall, early intravenous administration of β-blocker was beneficial in the pre-thrombolytic era, and controversial in the thrombolytic era. According to 2 studies conducted in the primary PCI era, intravenous administration of β-blocker before PCI seems to be beneficial; however, those studies were not randomized and the analysis was post hoc. Landiolol hydrochloride is an ultra-short-acting, β1-selective adrenergic receptor blocking agent for intravenous use that has been recently developed in Japan. Landiolol has much higher cardioselectivity (β1/β2=225), shorter half-life (4 min), and less effect on blood pressure (BP) than esmolol, a typical short-acting β1-receptor-selective blocker for intravenous use. 13, 14 Because patients in the very acute phase of AMI often have unstable hemodynamics, it may be difficult to use a β-blocker in every patient. Because landiolol has little effect on BP, it could possibly be used safely in the very acute phase of AMI with little concern for the developments of congestive heart failure or cardiogenic shock. Even if any adverse effects develop, the effect of landiolol rapidly disappears after withdrawal of administration. Although landiolol has been used to control tachyarrhythmias during and after cardiac surgery in Japan, little is known about the efficacy and safety of early intravenous administration of landiolol in patients with AMI. The aim of this study was to examine this issue in patients with AMI undergoing primary PCI in a prospective, randomized design.
Methods
This study was approved by the institutional ethics committee on human research. Written informed consent was given by all patients before the study.
Patients and Protocols
A consecutive 96 patients with ST-elevated MI transferred between January 2009 and March 2010 and undergoing primary PCI were enrolled. The diagnosis of AMI was made from the presence of typical prolonged chest pain accompanied by ST elevation on the 12-lead ECG and increases in the MB fraction of creatine kinase (CK) greater than twice the normal upper limit and of troponin T ≥0.1 ng/ml. All patients underwent emergency coronary angiography and PCI with coronary stenting within 12 h after the onset of AMI. The following patients were excluded from this study: those with Killip class 3 or 4, bradycardia <50 beats/min, hypotension with systolic BP <90 mmHg, bronchospasm, or second-or third-degree atrioventricular block. Just after PCI, the patients were randomly divided into 2 groups by an envelope method: 47 patients were assigned to landiolol and 49 to the control group. The intravenous infusion of landiolol (Ono Pharmaceutical Co, Ltd, Osaka, Japan) was started at 3 μg · kg -1 · min -1 without loading and continued for 24 h. If the patient showed any bradycardia <50 beats/min or hypotension with systolic BP <90 mmHg during landiolol administration, the infusion was stopped. We measured HR, systolic and diastolic BP on admission and continuously during PCI and for 24 h after PCI. Also the incidences of ventricular fibrillation (Vf), sustained ventricular tachycardia (VT), unsustained VT, and newly developed atrial fibrillation (AF) in the first 24 h were recorded. Blood biochemistry was measured on admission (day 1) and in the chronic phase (6 months after the onset of AMI). Cardiovascular events, including cardiac death, re-infarction, stroke, transient ischemic attack (TIA), emergency coronary artery bypass grafting (CABG), and admission for heart failure, were evaluated. Antegrade coronary blood flow was evaluated using the Thrombolysis In Myocardial Infarction (TIMI) scale. 15 
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Measurement of LV Volume and Function
All patients underwent cardiac catheterization including left ventriculography (LVG) at approximately 14 days and at 6 months after the onset of AMI. Two cardiologists who were unaware of the treatment assignment (landiolol or control) analyzed the LVG results. The ventricular tracings at end-diastole and end-systole in the 30-degree right anterior oblique projection were digitized with a cardiovascular measurement system (Medis Medical Imaging Systems, Nuenen, the Netherlands), and left ventricular end-diastolic and end-systolic volume indexes (LVEDVI, LVESVI), and LVEF were determined.
Statistical Analysis
The primary endpoint was to assess the efficacy of landilol in the acute phase and during a 6-month follow-up. For this endpoint, we assessed the incidences of cardiovascular events such as cardiac arrhythmias and cardiac death comparatively in the landiolol and control groups. We also evaluated the effect of landiolol on LV function assessed by LVG. The secondary endpoint was to assess the safety of landiolol administration in the very acute phase of AMI. For this endpoint, we examined the effects of landiolol on HR and BP in comparison with the control group, and also observed carefully the development of any adverse effects. All results are expressed as mean ± 1 standard error. Comparisons between the landiolol and control groups were performed using the unpaired t-test. HR and systolic and diastolic BPs measured on admission and at 2 h after admission were compared using paired t-test. LVEDVI, LVESVI, and LVEF measured in the acute and chronic phases were also compared using the paired t-test. Categorical data were compared using the chi-square test or Fisher's exact test. A P value less than 0.05 was regarded as significant. Table 1 shows the profiles of the patients in the landiolol (n=47) and control (n=49) groups. There were no significant differences between the 2 groups in the baseline characteristics, time from onset to the first balloon during primary PCI, or in the affected vessels. The severity of AMI determined by the Killip classification and maximum CK values did not differ between the 2 groups. None of the frequency of use of intraaortic balloon pumping, final TIMI flow grade, and Forrester subset classes showed any differences between the 2 groups. There were no differences between the 2 groups in medications at discharge and in the chronic phase, which included angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker, oral β-blocker, statin, calcium-channel blocker, diuretics, and nitrates ( Table 2) . None of the patients took oral β-blocker before the onset of AMI, and the day of the initiation of oral β-blocker after admission was similar between the 2 groups.
Results

Patients' Profiles
Blood Biochemistry Data
There were no significant differences between the 2 groups in the levels of serum creatinine, lipids, HbA1c, high-sensitivity C-reactive protein and plasma B-type natriuretic peptide (BNP) 
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measured on admission and in the chronic phase ( Table 3) . Table 4 shows the incidence of arrhythmias occurring in the first 24 h after admission. There were no cases of VT or Vf in either the landiolol or control group. The incidences of unsustained VT and AF did not differ between the 2 groups. Table 5 shows the incidences of cardiovascular events during admission in the acute phase and for the 6-month follow-up period for the landiolol and control groups. There were no cardiovascular events in either group during admission in the acute phase. One patient with an inferior AMI in the control group suffered from anterior AMI 3 months after the discharge. This patient was transferred back to hospital and treated with primary PCI, resulting in recanalization of the occluded artery. Another patient in the control group was hospitalized because of congestive heart failure 2 months after discharge. No significant difference between the landiolol and control groups was found in the incidence of cardiovascular events.
Effects of Landiolol on Cardiovascular Events and LVG Parameters
Figure shows the results of analysis of LVG in the acute (approximately 14 days after primary PCI) and chronic (6 months after primary PCI) phases. In 3 patients of the landiolol group and 2 of the control group, LVG was not obtained in either acute or chronic phase, so the final analysis was performed in 44 landiolol and 47 control group patients. LVEDVI increased from 72.5±2.8 ml/m 2 in the acute phase to 78.0± 2.7 ml/m 2 in the chronic phase (P=0.02) in the control group, whereas no significant difference was found in the landiolol group (from 76.6±3.3 to 81.8±4.2 ml/m 2 , P=NS). LVEF increased from 49.1±1.5% in the acute phase to 52.0±1.5% in the chronic phase (P=0.01) in the landiolol group, whereas no significant difference was found in the control group (from 50.2±1.4% to 50.2±1.2%, P=NS). LVESVI did not change from the acute to the chronic phase in either the landiolol or control group. Table 4 shows the HR and systolic and diastolic BPs on admission and at 2 h after admission for the landiolol and control groups. In the landiolol group, HR decreased from 80.0± 2.3 beats/min on admission to 70.1±1.7 beats/min at 2 h after admission (P<0.01), whereas it did not change in the control group (from 79.1±1.7 to 77.0±1.8 beats/min, P=NS).
Changes in BP and HR After Landiolol Administration
Systolic BP decreased in both the landiolol (from 126±2.6 to 117±2.4 mmHg, P<0.01) and control (from 131±2.6 to 119±2.0 mmHg, P<0.01) groups. When the changes in systolic BP were compared between the 2 groups, no difference was found (9.6±2.3 in landiolol vs. 12.1±2.0 mmHg in control group, P=NS). Diastolic BP decreased in both the landiolol (from 74±1.7 to 67±1.6 mmHg, P<0.01) and control (from 74±1.8 to 68±1.7 mmHg, P<0.01) groups, and no difference was found between landiolol and control groups (6.6±1.5 vs.
5.3±1.4 mmHg, P=NS).
Adverse Effects of Landiolol
One patient in the landiolol group showed bradycardia at a rate of 50 beats/min at 12 h after administration, which recovered approximately 10 min after discontinuation of the drug. Any other adverse effects of landiolol were not noted during administration.
Discussion
This is the first randomized prospective study to evaluate the 
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effects and safety of landiolol administered in the very acute phase of AMI. The major findings are as follows: (1) cardiovascular events in the acute phase and during a 6-month follow-up period were similar between the landiolol and control groups; (2) LVEF assessed 6 months later was greater than that at 2 weeks in the landiolol group, whereas it remained unchanged in control group. LVEDVI assessed 6 months later was increased in the control group, but unchanged in the landiolol group; (3) landiolol decreased HR by 10 beats/min without an excessive decrease in BP; (4) 1 patient in the landiolol group had bradycardia <50 beats/min, which recovered smoothly after discontinuation of the drug. The 2004 European Society of Cardiology Expert Consensus Document 16 on β-blockers stated that intravenous administration should be considered in patients with ischemic pain resistant to opiates, recurrent ischemia, and for the control of hypertension, tachycardia, and arrhythmias (class I indication). Intravenous β-blockers to limit infarct size have a class II recommendation. The 2004 American College of Cardiology/ American Heart Association guidelines 2 state that "it is reasonable to administer intravenous β-blockers promptly to the patients with ST-elevated myocardial infarction (STEMI) and without any contraindications, especially if a tachyarrhythmia or hypertension is present" (class IIa recommendation). Furthermore, "β-blockers should not be administered to patients with frank cardiac failure evidenced by pulmonary congestion or signs of a low-output state" (class III recommendation). These guidelines might be influenced by the few trials done more than 20 years ago when reperfusion therapy was not performed and intravenous β-blocker followed by oral administration was used as a monotherapy for AMI. 6- 8 The treatment environments in those studies differ from those in contemporary practice. 8 In the present study, landiolol administration just after PCI was not associated with the development of cardiogenic shock or congestive heart failure in the acute phase, and it improved LVEF and inhibited the increase of LVEDVI in the chronic phase. The incidence of cardiovascular events was low in both the landiolol and control group, which may be related to the effect of primary PCI for the culprit lesion. Only 1 patient showed bradycardia less than 50 beats/min after landiolol, but recovered smoothly after discontinuation of the drug without any residual complications. Landiolol is a derivative of esmolol, a typical short-acting β1-receptor-selective β-blocker for intravenous use, and has a much stronger β1-receptor affinity. Landiolol has less effects on BP and cardiac function than esmolol, 13,17,18 so appears to be suitable for patients who are apt to have unstable hemodynamics such as is seen in the very acute phase of AMI, with little concern of developing congestive heart failure or cardiogenic shock. Moreover, when adverse effects develop, the effect of landiolol rapidly disappears after its discontinuation. The manufacturer's recommended dose is 125 μg · kg -1 · min -1 for 1 min followed by 10-40 μg · kg -1 · min -1 . There is 1 study that evaluated the effect of landiolol in patients with normal or reduced cardiac function. 19 Landiolol decreased HR without affecting hemodynamics or LV function when administered at 40 μg · kg -1 · min -1 to patients with normal cardiac function, and HR returned to the baseline in 15 min after discontinuation of the drug. However, when the same dose was administered to patients with reduced cardiac function (LVEF <50%), mean arterial pressure and cardiac index were decreased. We used a dose of 3 μg · kg -1 · min -1 without loading and continued for 24 h. Landiolol has been used in 4 patients with cardiogenic shock, and hemodynamic deterioration did not occur. 20 Our results showed that landiolol administration was not associated with a reduced incidence of unsustained VT in the first 24 h after the onset of AMI. Although it has been shown that intravenous β-blocker reduced the incidence of fatal arrhythmias in the pre-thrombolytic era, there are only a few studies that have evaluated the antiarrhythmic effect of β-blockers in the reperfusion era. In the TIMI Phase II trial, early β-blocker administration in combination with thrombolytic therapy did not reduce the incidence of fatal arrhythmias compared with thrombolysis alone. 10 Intravenous β-blocker with thrombolytic therapy did not reduce the incidence of ventricular or supraventricular premature beats, unsustained VT, sustained VT, or Vf. 21 Overall, β-blocker therapy in the acute phase of AMI seems to have little effect on the occurrence of arrhythmias in the thrombolytic era, and our results were consistent with that.
Despite some beneficial mechanisms of early intravenous β-blocker having been reported, the actual mechanism is still unclear. Sympathetic hyperactivity occurs in patients with AMI, 22 which increases HR and cardiac contractility, being associated with increased cardiac oxygen consumption and thus myocardial ischemia. β-blockers reduce HR and cardiac contractility, thereby decrease myocardial oxygen demand, and thus slow the progression of necrosis in the peri-infarct tissue, preserve mitochondrial structures, and stabilize the vasculature. 23-26 Beta-blockers scavenge free radicals by binding to hydrophobic sites within the biological membrane, and this function may exert an antioxidant effect and protect cardiomyocytes from ischemic injury. 27,28
Study Limitations
The number of study patients was small, making it difficult to conclude the efficacy of landiolol. However, slowing the HR without affecting BP was caused by landiolol and therefore the drug would appear to be beneficial in patients in the very acute phase of AMI. The follow-up period was too short to evaluate cardiovascular events and prognosis.
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